N-acetylaminooctanoic acid | 80782-69-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-acetylaminooctanoic acid
• 英文别名: (+/-)-2-Acetamino-octansaeure-(1)；2-acetamidooctanoic acid
• CAS: 80782-69-0
• 化学式: C₁₀H₁₉NO₃
• 分子量: 201.266
• InChiKey: JJGNMSOJTSABGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-acetylaminooctanoic acid 、 (R)-(-)-甘油醇缩丙酮 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 2-acetamidooctanoate 、 (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 2-acetamidooctanoate
  参考文献：
  名称：

  环磷脂酸的合成和水解稳定性：对合成和原始细胞研究的影响

  摘要：

  环磷脂酸 (cPA) 是具有治疗潜力的生物活性化合物，但供不应求。我们描述了采用有效的环磷酸化程序的 cPA 的稳健合成，并报告了它们的水解特性——这应该有助于研究它们的生物学特性以及作为合理的原始细胞和合成细胞成分。

  DOI：

  10.1039/d2cc00292b
• 作为产物：
  描述：

  Acetamino-hexyl-malonsaeure-diaethylester 生成 N-acetylaminooctanoic acid
  参考文献：
  名称：

  取代了乙酰氨基丙酸酯和DL-2-乙酰氨基酸作为抗肿瘤剂。

  摘要：

  DOI：

  10.1002/jps.2600500413

文献信息

• SET OF BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME
  申请人：Cardiomix S.r.l.

  公开号：EP3865591A1

  公开（公告）日：2021-08-18

  The present invention relates to a specific set of circulating biomarkers and related methods and kits for the diagnosis of Brugada Syndrome in a human being.

  本发明涉及一组特定的循环生物标志物及相关方法和试剂盒，用于诊断人类的布鲁格达综合征。
• OMEGA-AMINO ACID DERIVATIVES, PROCESSES OF THEIR PREPARATION AND THEIR USE
  申请人：Biochemie S.R.O.

  公开号：EP0973710A2

  公开（公告）日：2000-01-26
• DIAGNOSTIC FOR MATERNAL RISK OF HAVING A CHILD WITH AUTISM SPECTRUM DISORDER
  申请人：Arizona Board of Regents on behalf of Arizona State University

  公开号：EP3947732A2

  公开（公告）日：2022-02-09
• THERAPEUTIC SYSTEMS USING MAGNETIC FIELDS
  申请人：University of Iowa Research Foundation

  公开号：US20210052910A1

  公开（公告）日：2021-02-25

  A system may comprise one, two or more magnetic field systems. The magnetic field system may be configured to provide a magnetic field in a first direction to the tissue. The magnetic field system may include at least one magnetic field source to produce the magnetic field. The magnetic field produced by the at least one magnetic field source may include a magnetic field produced by at least one of a permanent magnet, a temporary magnet or electric current flow through a conductor. The same or a second magnetic field system may be configured to provide a second magnetic field in a second direction to the tissue. The magnetic field system may include two or more sources to provide the magnetic field in a second, third or fourth direction that is non-parallel to the first direction.
• MONITORING EFFICACY OF MAGNETIC AND ELECTRIC FIELDS USING BIOMARKERS
  申请人：University of Iowa Research Foundation

  公开号：US20220118269A1

  公开（公告）日：2022-04-21

  An example may deliver a therapy by delivering energy to tissue. A method may include delivering energy to the tissue by providing a magnetic field in a first direction to the tissue using a magnetic field system including a magnetic field source to produce the magnetic field, wherein the magnetic field produced by the magnetic field source includes a magnetic field produced by at least one of a permanent magnet, a temporary magnet or electric current flow through a conductor, and providing an electric field in a second direction to the tissue using an electric field system including an electric field source to produce the electric field, wherein the second direction is non-parallel to the first direction. The method may further include detecting biomarker(s) within at least one of a redox system and a metabolic system to monitor efficacy of the therapy and/or calibrate or adjust the therapy.